Deciphera Pharmaceuticals, Inc. (DCPH)

Market Cap	1.07B
Revenue (ttm)	151.41M
Net Income (ttm)	-193.69M
Shares Out	80.12M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,573
Open	13.32
Previous Close	13.35
Day's Range	13.05 - 13.32
52-Week Range	9.90 - 22.76
Beta	0.50
Analysts	Buy
Price Target	22.56 (+70.65%)
Earnings Date	Oct 30, 2023

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 28, 2017
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: DCPH

Financial Performance

In 2022, DCPH's revenue was $134.04 million, an increase of 39.41% compared to the previous year's $96.15 million. Losses were -$178.93 million, -40.35% less than in 2021.

Analyst Forecast

According to 10 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is $22.56, which is an increase of 70.65% from the latest price.

Price Target

$22.56

(70.65% upside)

Analyst Consensus: Buy